|
1
|
Flaherty KT, Hodi FS and Fisher DE: From
genes to drugs: Targeted strategies for melanoma. Nat Rev Cancer.
12:349–361. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Simões MC, Sousa JJ and Pais AA: Skin
cancer and new treatment perspectives: A review. Cancer Lett.
357:8–42. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bollag G, Tsai J, Zhang J, Zhang C,
Ibrahim P, Nolop K and Hirth P: Vemurafenib: The first drug
approved for BRAF-mutant cancer. Nat Rev Drug Discov. 11:873–886.
2012. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Holderfield M, Deuker MM, McCormick F and
McMahon M: Targeting RAF kinases for cancer therapy: BRAF-mutated
melanoma and beyond. Nat Rev Cancer. 14:455–467. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Strickland LR, Pal HC, Elmets CA and Afaq
F: Targeting drivers of melanoma with synthetic small molecules and
phytochemicals. Cancer Lett. 359:20–35. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Romano E, Pradervand S, Paillusson A,
Weber J, Harshman K, Muehlethaler K, Speiser D, Peters S, Rimoldi D
and Michielin O: Identification of multiple mechanisms of
resistance to vemurafenib in a patient with
BRAFV600E-mutated cutaneous melanoma successfully
rechallenged after progression. Clin Cancer Res. 19:5749–5757.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Paraiso KH, Haarberg HE, Wood E, Rebecca
VW, Chen YA, Xiang Y, Ribas A, Lo RS, Weber JS, Sondak VK, et al:
The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance
mediated through diverse mechanisms. Clin Cancer Res. 18:2502–2514.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Falkenberg KJ and Johnstone RW: Histone
deacetylases and their inhibitors in cancer, neurological diseases
and immune disorders. Nat Rev Drug Discov. 13:673–691. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kaliszczak M, Trousil S, Åberg O, Perumal
M, Nguyen QD and Aboagye EO: A novel small molecule hydroxamate
preferentially inhibits HDAC6 activity and tumour growth. Br J
Cancer. 108:342–350. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu J, Gu J, Feng Z, Yang Y, Zhu N, Lu W
and Qi F: Both HDAC5 and HDAC6 are required for the proliferation
and metastasis of melanoma cells. J Transl Med. 14:72016.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Woan KV, Lienlaf M, Perez-Villaroel P, Lee
C, Cheng F, Knox T, Woods DM, Barrios K, Powers J, Sahakian E, et
al: Targeting histone deacetylase 6 mediates a dual anti-melanoma
effect: Enhanced antitumor immunity and impaired cell
proliferation. Mol Oncol. 9:1447–1457. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang L, Xiang S, Williams KA, Dong H, Bai
W, Nicosia SV, Khochbin S, Bepler G and Zhang X: Depletion of HDAC6
enhances cisplatin-induced DNA damage and apoptosis in non-small
cell lung cancer cells. PLoS One. 7:e442652012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang Z, Hu P, Tang F, Lian H, Chen X,
Zhang Y, He X, Liu W and Xie C: HDAC6 promotes cell proliferation
and confers resistance to temozolomide in glioblastoma. Cancer
Lett. 379:134–142. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yoshida M, Furumai R, Nishiyama M, Komatsu
Y, Nishino N and Horinouchi S: Histone deacetylase as a new target
for cancer chemotherapy. Cancer Chemother Pharmacol. 48:(Suppl 1).
S20–S26. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Krämer OH, Mahboobi S and Sellmer A:
Drugging the HDAC6-HSP90 interplay in malignant cells. Trends
Pharmacol Sci. 35:501–509. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yang Y, Ran J, Liu M, Li D, Li Y, Shi X,
Meng D, Pan J, Ou G, Aneja R, et al: CYLD mediates ciliogenesis in
multiple organs by deubiquitinating Cep70 and inactivating HDAC6.
Cell Res. 24:1342–1353. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Santo L, Hideshima T, Kung AL, Tseng JC,
Tamang D, Yang M, Jarpe M, van Duzer JH, Mazitschek R, Ogier WC, et
al: Preclinical activity, pharmacodynamic, and pharmacokinetic
properties of a selective HDAC6 inhibitor, ACY-1215, in combination
with bortezomib in multiple myeloma. Blood. 119:2579–2589. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Raje N, Vogl DT, Hari PN, et al: ACY-1215,
a selective histone deacetylase (HDAC) 6 inhibitor: Interim results
of combination therapy with bortezomib in Patients with multiple
myeloma (MM). Blood. 122:7592013.PubMed/NCBI
|
|
19
|
Pandey UB, Nie Z, Batlevi Y, McCray BA,
Ritson GP, Nedelsky NB, Schwartz SL, DiProspero NA, Knight MA,
Schuldiner O, et al: HDAC6 rescues neurodegeneration and provides
an essential link between autophagy and the UPS. Nature.
447:859–863. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lee JY, Koga H, Kawaguchi Y, Tang W, Wong
E, Gao YS, Pandey UB, Kaushik S, Tresse E, Lu J, et al: HDAC6
controls autophagosome maturation essential for ubiquitin-selective
quality-control autophagy. EMBO J. 29:969–980. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Senft D and Ronai ZA: UPR, autophagy, and
mitochondria crosstalk underlies the ER stress response. Trends
Biochem Sci. 40:141–148. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Beck D, Niessner H, Smalley KS, Flaherty
K, Paraiso KH, Busch C, Sinnberg T, Vasseur S, Iovanna JL, Drießen
S, et al: Vemurafenib potently induces endoplasmic reticulum
stress-mediated apoptosis in BRAFV600E melanoma cells. Sci Signal.
6:ra72013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rodvold JJ, Mahadevan NR and Zanetti M:
Immune modulation by ER stress and inflammation in the tumor
microenvironment. Cancer Lett. 380:227–236. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Rutkowski DT and Kaufman RJ: A trip to the
ER: Coping with stress. Trends Cell Biol. 14:20–28. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Oyadomari S and Mori M: Roles of
CHOP/GADD153 in endoplasmic reticulum stress. Cell Death Differ.
11:381–389. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Rizos H, Menzies AM, Pupo GM, Carlino MS,
Fung C, Hyman J, Haydu LE, Mijatov B, Becker TM, Boyd SC, et al:
BRAF inhibitor resistance mechanisms in metastatic melanoma:
Spectrum and clinical impact. Clin Cancer Res. 20:1965–1977. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Samatar AA and Poulikakos PI: Targeting
RAS-ERK signalling in cancer: Promises and challenges. Nat Rev Drug
Discov. 13:928–942. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tien SC and Chang ZF: Oncogenic Shp2
disturbs microtubule regulation to cause HDAC6-dependent ERK
hyperactivation. Oncogene. 33:2938–2946. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ott PA, Hodi FS and Robert C: CTLA-4 and
PD-1/PD-L1 blockade: New immunotherapeutic modalities with durable
clinical benefit in melanoma patients. Clin Cancer Res.
19:5300–5309. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Merelli B, Massi D, Cattaneo L and Mandalà
M: Targeting the PD1/PD-L1 axis in melanoma: Biological rationale,
clinical challenges and opportunities. Crit Rev Oncol Hematol.
89:140–165. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tumeh PC, Harview CL, Yearley JH, Shintaku
IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu
V, et al: PD-1 blockade induces responses by inhibiting adaptive
immune resistance. Nature. 515:568–571. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hao M, Song F, Du X, Wang G, Yang Y, Chen
K and Yang J: Advances in targeted therapy for unresectable
melanoma: New drugs and combinations. Cancer Lett. 359:1–8. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lienlaf M, Perez-Villarroel P, Knox T,
Pabon M, Sahakian E, Powers J, Woan KV, Lee C, Cheng F, Deng S, et
al: Essential role of HDAC6 in the regulation of PD-L1 in melanoma.
Mol Oncol. 10:735–750. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Prahallad A, Sun C, Huang S, Di
Nicolantonio F, Salazar R, Zecchin D, Beijersbergen RL, Bardelli A
and Bernards R: Unresponsiveness of colon cancer to BRAF(V600E)
inhibition through feedback activation of EGFR. Nature.
483:100–103. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Corcoran RB, Ebi H, Turke AB, Coffee EM,
Nishino M, Cogdill AP, Brown RD, Pelle P Della, Dias-Santagata D,
Hung KE, et al: EGFR-mediated re-activation of MAPK signaling
contributes to insensitivity of BRAF mutant colorectal cancers to
RAF inhibition with vemurafenib. Cancer Discov. 2:227–235. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Gao YS, Hubbert CC and Yao TP: The
microtubule-associated histone deacetylase 6 (HDAC6) regulates
epidermal growth factor receptor (EGFR) endocytic trafficking and
degradation. J Biol Chem. 285:11219–11226. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Deribe YL, Wild P, Chandrashaker A, Curak
J, Schmidt MH, Kalaidzidis Y, Milutinovic N, Kratchmarova I,
Buerkle L, Fetchko MJ, et al: Regulation of epidermal growth factor
receptor trafficking by lysine deacetylase HDAC6. Sci Signal.
2:ra842009.PubMed/NCBI
|
|
38
|
Wang Z, Hu P, Tang F and Xie C:
HDAC6-mediated EGFR stabilization and activation restrict cell
response to sorafenib in non-small cell lung cancer cells. Med
Oncol. 33:502016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wang Z, Tang F, Hu P, Wang Y, Gong J, Sun
S and Xie C: HDAC6 promotes cell proliferation and confers
resistance to gefitinib in lung adenocarcinoma. Oncol Rep.
36:589–597. 2016.PubMed/NCBI
|
|
40
|
Sanduja S, Feng Y, Mathis RA, Sokol ES,
Reinhardt F, Halaban R and Gupta PB: AMPK promotes tolerance to Ras
pathway inhibition by activating autophagy. Oncogene. 35:5295–5303.
2016. View Article : Google Scholar : PubMed/NCBI
|
